Immunity enhancing in Rheumatoid Arthritis

EFFICACY OF AYURVEDIC RASAYANA COMPOUND(IMMUNOMODULATION)IN AMAVATA WITH SPECIAL REFERENCE TO RHEUMATOID ARTHRITIS,AN OPEN RANDOMIZED COMPARATIVE CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027370

Enrollment

Registered

2020-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

Intervention1: Chitrkadi vati Erand tail Ashwagandha churna Shatavari churna Guduchi churna Kutki churna: 1.Chitrkadi vati 2 tab thrice a day for 3 days with lukewarm water 2.sadya virechan with erand

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients having the clinical manifestation of Amavata (RA) according to Ayurvedic classics - SANDHISHOOL (PAIN), SHOTH (SWELLING), SPARSHASAHTA (TENDERNESS) and STABDHATA (STIFFNESS) Angamarda, Aruchi, Trishna, Alasya, Gaurava, Jwar , Apaka, Shoonataanganam, Agnidaurbalya, Praseka, Vairasya, Ruja, and Shotha in Hasta, Pada, Shiro, Gulpha, Trika, Janu, Uru Sandhi, VrishchikaDanshavataVedana,Vibandha, Nidra-Viparyaya, Daha, Bahumutrata 2) Patients having positive RA factor. 3) The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis Score.

Exclusion criteria

Exclusion criteria: 1.Patients with other systemic complications of RA like RHD, Rheumatic fever, pleural â?? pericardial disease. Patients with poorly controlled Hypertension ( >160/100 mm of Hg). 2.Patients diagnosed with other arthritis like gouty arthritis, tuberculous arthritis, etc. 3.Patients who are unable to walk without support and / or confined to wheel chair. 4.H/o hypersensitivity to any of the trial drugs or their ingredients. 5.Pregnant / lactating woman. 6.Patients who have completed participation in any other clinical trial during the past 6 months.

Design outcomes

Primary

Measure	Time frame
To see rasayana effect (Immunomodulation) in Amavata pateints (Rheumatoid arthritis- auto immune disorder) Timepoint: 44 days	—

Secondary

Measure	Time frame
1.To provide relief in the cardinal symptoms of Amavata (RA) - sandhishoola (pain), shotha (swelling), sparsh-asahta (tenderness) and stabhta (stiffness). 2.Improves the quality of life of Amavata patients. 3.Significant decrease in values (quantitative) of ESR,RA FACTOR, IgM 3.Gradual increase in Hb% value.Timepoint: 44 days	—

Countries

India

Contacts

Public ContactDr Gunjan Patheja

All India Institute of Ayurveda

drrky68@gmail.com9412148437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026